SCOPUS 정보 검색 플랫폼

Volumn 48, Issue 12, 2008, Pages 1420-1429

Model-based development of a PPARγ agonist, rivoglitazone, to aid dose selection and optimize clinical trial designs

(8) Rohatagi, Shashank a Carrothers, Timothy J b Jin, JinYan c Jusko, William J c Khariton, Tatiana b Walker, Joseph a Truitt, Kenneth a Salazar, Daniel E a

a DAIICHI SANKYO INC (United States)

b PHARSIGHT CORPORATION (United States)

c UNIVERSITY AT BUFFALO (United States)

Author keywords

Exposure response; Learn and confirm; Pharmacodynamics; Population pharmacokinetics; Rivoglitazone

Indexed keywords

ADIPONECTIN; HEMOGLOBIN A1C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PLACEBO; RIVOGLITAZONE;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; EDEMA; FEMALE; GLUCOSE BLOOD LEVEL; HEMODILUTION; HUMAN; HUMAN EXPERIMENT; INDIVIDUALIZATION; INTERSUBJECT VARIABILITY; KIDNEY FUNCTION; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEX RATIO; TANDEM MASS SPECTROMETRY; VOLUNTEER;

ADIPONECTIN; ADMINISTRATION, ORAL; ALGORITHMS; BLOOD GLUCOSE; CHROMATOGRAPHY, LIQUID; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; METABOLIC CLEARANCE RATE; MODELS, BIOLOGICAL; PPAR GAMMA; RESEARCH DESIGN; TANDEM MASS SPECTROMETRY; THIAZOLIDINEDIONES;

EID: 57449120900 PISSN: 00912700 EISSN: 15524604 Source Type: Journal
DOI: 10.1177/0091270008323260 Document Type: Article

Times cited : (21)

References (14)

1
- 13644263258
- Oral antidiabetic agents: Current role in type 2 diabetes mellitus
- Krentz AJ, Bailey CJ Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs. 2005 ; 65: 385-411.
- (2005) Drugs , vol.65 , pp. 385-411
- Krentz, A.J.¹ Bailey, C.J.²

2
- 0038460622
- Thiazolidinediones in type 2 diabetes mellitus: Current clinical evidence
- Diamont M., Heine RJ Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence. Drugs. 2003 ; 63: 1373-1405.
- (2003) Drugs , vol.63 , pp. 1373-1405
- Diamont, M.¹ Heine, R.J.²

3
- 57449101797
- Single and multiple dose pharmacokinetics and pharmacodynamics of rivoglitazone (CS-011) in healthy male volunteers
- Walker JR, Triscari J., Dmuchowski CF, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of rivoglitazone (CS-011) in healthy male volunteers. J Clin Pharmacol. 2006 ; 46: 1069.
- (2006) J Clin Pharmacol , vol.46 , pp. 1069
- Walker, J.R.¹ Triscari, J.² Dmuchowski, C.F.³

4
- 57449085287
- The steady-state pharmacokinetics of rivoglitazone (CS-011) are not affected by co-administration of the potent CYP3A4 inhibitor itraconazole
- Walker JR, Dmuchowski CF, Samata N., Salazar DE The steady-state pharmacokinetics of rivoglitazone (CS-011) are not affected by co-administration of the potent CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther. 2007 ; 81: S40.
- (2007) Clin Pharmacol Ther. , vol.81 , pp. 40
- Walker, J.R.¹ Dmuchowski, C.F.² Samata, N.³ Salazar, D.E.⁴

5
- 57449110304
- A randomized, placebo-controlled, double-blind comparative study of rivoglitazone and open-label pioglitazone in patients with type 2 diabetes
- Truitt K., Chou HS, Wang A., Walker JR, Rosenstock J. A randomized, placebo-controlled, double-blind comparative study of rivoglitazone and open-label pioglitazone in patients with type 2 diabetes. Presented at: Annual Meeting of the American Diabetes Association ; June 14-17, 2008 ; San Francisco.
- Presented At: Annual Meeting of the American Diabetes Association
- Truitt, K.¹ Chou, H.S.² Wang, A.³ Walker, J.R.⁴ Rosenstock, J.⁵

6
- 57449114490
- A randomized, placebo-controlled, 26-week dose response study of rivoglitazone versus pioglitazone in subjects with type 2 diabetes
- Chou HS, Wang A., Walker JR, Truitt K., Rosenstock J. A randomized, placebo-controlled, 26-week dose response study of rivoglitazone versus pioglitazone in subjects with type 2 diabetes. Presented at: Annual Meeting of the American Diabetes Association ; June 14-17, 2008 ; San Francisco.
- Presented At: Annual Meeting of the American Diabetes Association
- Chou, H.S.¹ Wang, A.² Walker, J.R.³ Truitt, K.⁴ Rosenstock, J.⁵

7
- 0031003468
- Learning versus confirming in drug development
- Sheiner LB Learning versus confirming in drug development. Clin Pharmacol Ther. 1997 ; 61: 275-291.
- (1997) Clin Pharmacol Ther , vol.61 , pp. 275-291
- Sheiner, L.B.¹

8
- 33745834319
- Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
- Kadowaki T., Yamauchi T., Kubota N., Hara K., Ueki K., Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006 ; 116: 1784-1792.
- (2006) J Clin Invest , vol.116 , pp. 1784-1792
- Kadowaki, T.¹ Yamauchi, T.² Kubota, N.³ Hara, K.⁴ Ueki, K.⁵ Tobe, K.⁶

9
- 36249008034
- Adiponectin circulating levels: A new emerging biomarker of cardiovascular risk
- Giannessi D., Maltinti M., Del Ry S. Adiponectin circulating levels: a new emerging biomarker of cardiovascular risk. Pharmacol Res. 2007 ; 56: 459-467.
- (2007) Pharmacol Res , vol.56 , pp. 459-467
- Giannessi, D.¹ Maltinti, M.² Del Ry, S.³

10
- 57449112282
- The effects of rivoglitazone on adiponectin in healthy subjects
- Triscari J., Dmuchoswski C., Matthews P. The effects of rivoglitazone on adiponectin in healthy subjects. Diabetes. 2006 ; 55: A136.
- (2006) Diabetes , vol.55 , pp. 136
- Triscari, J.¹ Dmuchoswski, C.² Matthews, P.³

11
- 57449117844
- Geneva, Switzerland: World Intellectual Property Organization;
- Benincosa L., Jusko WJ Novel Method of Treatment. Geneva, Switzerland: World Intellectual Property Organization ; 1999.
- (1999) Novel Method of Treatment
- Benincosa, L.¹ Jusko, W.J.²

12
- 0003556719
- Rockville, MD: US Department of Health and Human Services, FDA ;
- Food and Drug Administration. Guidance for Industry Population Pharmacokinetics. Rockville, MD: US Department of Health and Human Services, FDA ; 1999. Available at: www.fda.gov/cder/guidance/1852fnl.pdf.
- (1999) Guidance for Industry Population Pharmacokinetics
- Food¹ Administration, D.²

13
- 57449092035
- When to conduct a renal impairment study
- Huang SW When to conduct a renal impairment study. Presented at: Clinical Pharmacology Advisory Committee Meeting ; March 19, 2008 ; Rockville, MD.
- Presented At: Clinical Pharmacology Advisory Committee Meeting
- Huang, S.W.¹

14
- 33745779941
- A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and glyclazide on disease processes underlying type 2 diabetes mellitus
- De Winter W., deJongh H., Post T., et al. A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and glyclazide on disease processes underlying type 2 diabetes mellitus. J Pharmacokin Pharmacodyn. 2006 ; 33: 313-343.
- (2006) J Pharmacokin Pharmacodyn , vol.33 , pp. 313-343
- De Winter, W.¹ Dejongh, H.² Post, T.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.